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Objectives: Liver transplantation (LT) in Milan Criteria (MC) hepatocellular carcinoma (HCC) has excel-
lent outcomes. Pre-transplant loco-regional therapy (LRT) has been used to downstage HCC to meet the
MC. However, its benefit in patients with a brief waiting time to transplant remains unclear. This study
evaluated outcomes in patients with short waitlist times to LT for MC-compliant HCC.
Methods: Patients undergoing LT for MC HCC at either of two transplant centres between 2002 and
2009 were retrospectively evaluated for outcome. Patients for whom post-transplant follow-up amounted
to <12 months were excluded.
Results: A total of 225 patients were included, 93 (41.3%) of whom received neoadjuvant LRT. The
median waiting time to transplant was 48 days. Mean post-transplant follow-up was 32.2 months. Overall
and disease-free survival at 1 year, 3 years and 5 years were 93.1%, 82.4% and 72.6%, and 91.3%,
79.3% and 70.6%, respectively. There was no difference in overall (P = 0.94) and disease-free survival
(P = 0.94) between groups who received and did not receive pre-LT LRT. There were also no disparities
in survival or tumour recurrence among categories of patients (with single tumours measuring <3 cm,
with single tumours measuring 3–5 cm, with multiple tumours).
Conclusions: Loco-regional therapy followed by rapid transplantation in MC HCC appears not to have
an impact on post-transplant outcome.
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Introduction
Liver transplantation (LT) holds the potential for cure in selected
patients with hepatocellular carcinoma (HCC) complicating cir-
rhosis.1,2 Patients with tumours within the Milan Criteria (MC)
(single lesions measuring 2–5 cm or up to three lesions measuring
<3 cm each) exhibit post-transplant 5-year disease-free survival of
75% and tumour recurrence rates of 8–12%.3 Therefore, efforts to
maintain HCCs within these criteria have driven the implemen-
tation of neoadjuvant loco-regional therapy (LRT) among trans-
plant centres.4
Although no post-transplant survival benefits of neoadjuvant
LRT have been observed, patients in whom advanced tumours are
unsuccessfully downstaged have exhibited worse outcomes.5,6
As a result, a good response to LRT has served as a surrogate for
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favourable tumour biology and has become a pivotal factor in the
selection of patients for transplant when HCC is beyond the
MC.7,8
Before the implementation of the Model for End-stage Liver
Disease (MELD) liver allocation system in 2002, waitlist times for
MC HCC patients were significantly longer. As a result, tumour
progression had a negative impact on waitlist dropout rates and
on patient survival.9 Because the current UNOS allocation system
enables MELD exception points for HCC patients within MC,
waitlist times are shorter and rates of dropout for reasons of
tumour progression have improved.10
Based on data suggesting that HCC lesions can double in size
within 6 months, current guidelines support the treatment of
patients with small tumours when waitlist time exceeds this
period.1 However, some transplant clinicians may consider the use
of neoadjuvant LRT even in the setting of short waitlist times,
arguing that induced tumour necrosis decreases tumour burden,
which can prevent vascular invasion and may reduce the risk for
tumour recurrence.
As the MC embraces a heterogeneous group of HCC patients,
there may be a role for neoadjuvant LRT in multifocal disease or
in single tumours measuring >3 cm in the setting of short waitlist
time. This potential is further emphasized by reports that tumour
burden is underestimated in 20–40% of cases by current cross-
sectional imaging technology.11–13 This postulate follows the
general oncologic principle of treating the disease in its early
stages; however, it holds some caveats. Although there are no large
randomized controlled trials (RCTs), available data reveal that
neoadjuvant LRT for small tumours in patients with short waitlist
times does not offer survival benefits or reduce tumour recurrence
rates.14 Secondly, the absence of accurate biomarkers predicting
tumour behaviour makes time after treatment the sole factor
capable of unveiling tumour biology.
In line with this, researchers have been able to identify patients
with HCC beyond the MC with post-transplant outcomes similar
to those of patients with MC-compliant HCC. In these cases,
patients who were successfully downstaged by neoadjuvant LRT
and exhibited no tumour progression over a particular length of
time (3 months) were selected for transplantation.4
More recently, the similar concept of ‘ablating and waiting’ has
been proposed for MC-compliant HCC patients in an effort to
reduce, although modestly, the risk for tumour relapse after trans-
plantation in this group of patients.15 Roberts et al.15 and Yao
et al.4 have raised concerns with regard to rapid transplantation
(within 3 months of LRT) in patients with HCC within and
beyond the MC, respectively. In an era of severe organ shortage,
such endeavours are well accepted and efforts to expand graft and
patient survival should be continuously fostered.
In order to expand existing data on this issue, this study reports
data for 93 patients with waitlist times of <6 months who received
pre-transplant LRT for MC-compliant HCC, and 132 similar
patients who did not receive pre-transplant LRT, during the
period from January 2002 to December 2009.
Materials and methods
This study was approved by the Cleveland Clinic and University
Hospitals Institutional Review Boards. Medical records for
patients who underwent LT for HCC from January 2002 to
December 2009 in Cleveland, Ohio at two institutions, Cleveland
Clinic and the University Hospital of Case Western Reserve Uni-
versity, were reviewed from a prospectively collected database.
Patients who died within 1 month after transplantation or who
underwent LT within 12 months of the review period (for whom
follow-up data were inadequate) were excluded. Patients with
HCC considered to fall within the MC were included in the study.
All patients were initially evaluated by members of a dedicated
team of hepatologists, hepatobiliary and LT surgeons, oncologists
and interventional radiologists with an interest in HCC. The diag-
nosis of HCC was determined based on radiological criteria
according to published guidelines1,16 or by histology. The manage-
ment of LRT was based on a consensus agreement among the
treating physicians. Loco-regional therapy interventions offered
included radiofrequency ablation (RFA), transarterial chemo-
embolization (TACE), bland embolization, drug (doxorubicin)
eluting bead (DEB) embolization, and Y90 radioembolization
with Therasphere® or SIR-Spheres®.
Data collection
Data collected included patient demographics, aetiology of liver
disease, MELD score, number and sizes of HCC lesions, loco-
regional treatments, time to LT, donor organ types (cadaver
donors including cardiac death donors, living donors), histopa-
thology of explanted livers, recurrence of HCC and patient death.
Radiological response was evaluated at 1–3 months after treat-
ment using triphasic computed tomography (CT) or magnetic
resonance imaging (MRI). Need for subsequent treatment was
defined by consensus agreement among the treating physicians.
Complete response was considered in the absence of residual
tumour enhancement.
At the time of transplantation, the size, number and distribu-
tion of HCC lesions, as well as the presence of tumour vascular
invasion and tumour differentiation (good, moderate, poor) were
determined by experienced liver pathologists. In patients who had
undergone LRT, the percentage of tumour necrosis was graded as
complete (100%), partial (50–99%) or poor (0–49%).
Data and statistical analysis
These variables were compared in patients whose HCC fulfilled
the MC, and who did and did not receive LRT, respectively.
For analysis of continuous variables in the two groups, Stu-
dent’s t-test or, if appropriate, non-parametric Wilcoxon rank
sum test was used. For comparison among multiple groups, analy-
sis of variance (anova) was used. Categorical variables were
analysed using Pearson’s chi-squared test or Fisher’s exact test.
Survival analysis was performed to assess post-transplant sur-
vival in each group. Kaplan–Meier plots were constructed and
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log-rank tests were used to compare the groups. Post-transplant
follow-up was defined as the time from transplant to either death
or the last follow-up visit. A P-value of <0.05 was considered to
indicate statistical significance. All analyses were performed using
sas Version 9.2 (SAS Institute, Inc., Cary, NC, USA).
Results
Between January 2002 and December 2009, 288 patients diag-
nosed with HCC underwent LT at the Cleveland Clinic and Uni-
versity Hospitals. Six patients died as a result of postoperative
complications within 1 month of transplantation. Follow-up at
the time of this data evaluation was insufficient (<12 months) for
seven patients. These 13 patients were excluded from the study. Of
the remaining 275 patients, 225 (81.8%) were identified as having
HCC within the MC at the initial radiological evaluation and were
included in the study.
Demographics and baseline characteristics
The majority of the patients were male (n = 180, 80.0%). The
mean  standard deviation (SD) age of the patients was 57.8 
8.4 years. Hepatitis C was the most common aetiology of liver
disease (62.2%). Fourteen 14 (6.2%) patients had liver disease of
more than one aetiology. A total of 93 (41.3%) patients had
received LRT prior to LT and 132 (58.7%) patients underwent LT
without prior LRT. There were no significant differences in patient
demographics and aetiology of liver disease between the study
groups (Table 1). Mean  SD follow-up time was 32.2  28
months and mean  SD waiting time to transplantation was
93.7  124 days. Mean waiting time to transplant was similar in
both groups (86.1 days vs. 99.1 days; P = 0.44). Median waiting
time to transplant was 48.0 days [confidence interval (CI)
25%: 20.5, 75%: 110] in the entire study population and was
similar in the two groups (54.0 days vs. 43.5 days; P = 0.44).
MELD scores at listing without exception points were lower in
the treated group (10.7 vs. 14.5; P < 0.0001). This difference was
less noticeable at transplantation (12.6 vs. 16.0; P = 0.052).
The most frequent LRT modality was TACE, offered to 58
(62.4%) patients, followed by RFA in 28 (30.1%) patients. The
other modalities offered were DEB in nine (9.7%) patients, bland
embolization in two (2.2%) patients, and Y90 radioembolization
in two (2.2%) patients. Six (6.5%) patients received a combination
of therapies. Overall, 86 (92.5%) patients received only one
session of therapy prior to LT and seven (7.5%) patients received
more than one session, one of whom received four sessions of
therapy prior to LT. The mean SD number of therapies prior to
LT in the treated group was 1.2  0.6.
Tumour characteristics by imaging
and histopathology
Radiological diagnosis and staging revealed no significant differ-
ence between the groups in the mean number of liver lesions (1.6
vs. 1.3; P = 0.19). However, tumours was larger (2.8 cm vs. 2.2 cm;
P = 0.002) in the group receiving LRT (Table 2). Similarly, evalu-
ation of explanted livers showed that lesions were larger in the
group undergoing LRT (3.3 cm vs. 2.6 cm; P = 0.001), but the
mean number of lesions (2.2 vs. 1.8) did not differ significantly
(P = 0.32).
Table 1 Demographic characteristics of patients
All (n = 225) Within Milan Criteria P-value
LRT group (n = 93) Non-LRT group (n = 132)
Age, years, mean  SD 57.8  8.4 58.6  9.4 57.2  7.6 0.24
Sex
Male, n (%) 180 (80.0) 73 (78.5) 107 (81.1) 0.64
Female, n (%) 45 (20.0) 20 (21.5) 25 (18.9) 0.64
Diagnosis, n (%) 0.28
Hepatitis C 140 (62.2) 59 (63.4) 81 (61.4)
Alcohol 36 (16.0) 13 (14.0) 23 (17.4)
Non-alcoholic fatty liver disease 24 (10.7) 10 (10.8) 14 (10.6)
Hepatitis B 16 (7.1) 4 (4.3) 12 (9.1)
Others 23 (10.2) 9 (9.7) 14 (10.6)
More than one diagnosis 14 (6.2) 2 (2.2) 12 (9.1)
MELD score at listing (without exception points), mean  SD 13  6.1 10.7  3.6 14.5  7 <0.0001
MELD score at transplant (without exception points), mean  SD 14.6  6 12.6  4.5 16  6.6 0.052
Transplant waiting time, days, mean  SD 93.7  124 86.1  121 99.1  127 0.44
Transplant waiting time, median, 25–75% CI 48 (20.5–110) 54 (29.5–87) 43.5 (15–147.5) 0.44
Follow-up time, months, mean  SD 32.2  28.2 30.1  34.1 33.7  23.1 0.38
LRT, loco-regional therapy; SD, standard deviation; MELD, Model for End-stage Liver Disease; CI, confidence interval.
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There was no difference between the groups in the presence of
vascular invasion (21.5% vs. 27.3%; P = 0.36). There was less
representation of well-differentiated tumours (11.8% vs. 23.4%;
P = 0.001) in the group that underwent LRT (Table 2).
A total of 52 (23.1%) patients in whom HCC was staged by
imaging as MC-compliant were re-staged as outside the MC on
examination of explanted livers. This occurred with equal fre-
quency in both groups (Table 2). In these patients, the mean SD
number of lesions was higher (1.8  1.2 vs. 1.3  0.9; P = 0.03),
tumour diameter was greater (3.2  1.3 vs. 2.1  1.1 cm;
P  0.001) and vascular invasion was more frequent (53.8% vs.
18.0%; P = 0.0002) than in the group in which HCC was not
re-staged as non-compliant with the MC on explant evaluation.
There were no differences in levels of tumour markers [alpha-
fetoprotein (AFP)] prior to LT between the groups (data not
shown). There was no difference in the source of organ donors
between the groups.
Survival analysis
Overall survival at 1 year, 3 years and 5 years in the whole study
population was 93.1%, 82.4% and 72.6%, respectively. Disease-
free survival in the entire cohort at 1 year, 3 years and 5 years was
91.3%, 79.3% and 70.6%, respectively. Analysis of overall survival
at 1 year, 3 years and 5 years in the groups receiving LRT (93.5%,
84.4% and 64.9%, respectively) and not receiving LRT (92.9%,
81.4% and 76.2%, respectively) revealed no statistical difference
(P = 0.94) (Fig. 1). Similarly, analysis of disease-free survival at 1
year, 3 years and 5 years in the treated (90.7%, 81.8% and 64.2%,
respectively) and non-treated (91.3%, 78.2% and 74.3%, respec-
tively) groups showed no statistical difference (P = 0.94) (Fig. 2).
Accordingly, the treated and non-treated groups showed similar
rates of tumour recurrence (11.8% vs. 9.8%; P = 0.64) and mor-
tality (19.4% vs. 18.2%; P = 0.82) during the mean follow-up
period of 32.2 months.
Subgroup analysis based on treatment response
In the LRT group, in patients who demonstrated a complete
radiological response, 1-, 3- and 5-year overall survival rates
(90.0%, 85.9% and 73.6%, respectively) and 1-, 3- and 5-year
recurrence-free survival rates (90.0%, 79.7% and 66.4%, respec-
tively) were comparable with rates of overall survival (P = 0.79)
and recurrence-free survival (P = 0.85) in patients who did not
demonstrate a complete radiological response. No patient or
tumour characteristics were indicated as significantly predicting a
higher likelihood of achieving a complete radiological response
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Figure 1 Kaplan–Meir survival curves: overall survival in the treated
and non-treated groups (P = 0.94). LRT, loco-regional therapy
Table 2 Tumour characteristics
All (n = 225) Within Milan Criteria P-value
LRT group (n = 93) Non-LRT group (n = 132)
Pre-transplant tumour characteristics (imaging)
Number of lesions, mean  SD 1.4  1 1.6  0.9 1.3  1 0.19
Size of the largest lesion, mean  SD 2.4  1.3 2.8  1.3 2.2  1.2 0.002
Single lesions, n (%) 108 (48.0) 37 (40.0) 71 (66.3) 0.28
Post-transplant tumour characteristics (on explant)
Number of lesions, mean  SD 2  2.4 2.2  3.5 1.8  1.5 0.32
Size of the largest lesion, mean  SD 2.9  1.5 3.3  1.8 2.6  1.2 0.001
Single lesions, n (%) 118 (52.4) 43 (46.2) 75 (56.8) 0.29
Margin invasion presence, n (%) 4 (1.8) 2 (2.2) 2 (1.5) 0.09
Vascular invasion presence, n (%) 56 (24.9) 20 (21.5) 36 (27.3) 0.36
Well differentiated tumour, n (%) 42 (18.7) 9 (11.8) 31 (23.4) 0.001
Pathology beyond MC, n (%) 52 (23.1) 24 (25.8) 28 (21.2) 0.30
SD, standard deviation; MC, Milan Criteria.
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Analysis of data for 16 patients who achieved complete tumour
necrosis in the explanted liver showed better 1-, 3- and 5-year
overall survival (100%, 100% and 100%, respectively) and 1-, 3-
and 5-year recurrence-free survival (100%, 100% and 100%,
respectively) than patients who did not achieve complete necrosis
among the treated group of 93 patients (P = 0.07 and P = 0.09,
respectively). However, no patient or tumour characteristics were
significantly associated with a higher likelihood of achieving com-
plete tumour necrosis following LRT (Table 3).
There was no significant difference between patients in whom
explanted tumours were found to have been radiologically under-
staged and those in whom explanted tumours were found to have
been accurately staged in overall survival (P = 0.68) or disease-free
survival (P = 0.74). Among patients who were radiologically
understaged, there were no differences in overall 1-, 3- and 5-year
survival between the LRT group (100%, 80.8% and 41.0%, respec-
tively) and the non-LRT group (88.8%, 75.5% and 62.9%, respec-
tively) (P = 0.75). Similarly, no statistical difference in 1-, 3- and
5-year disease-free survival emerged between the LRT group
(89.6%, 69.3% and 31.7%, respectively) and the non-LRT group
(81.0%, 70.5% and 47.0%, respectively) (P = 0.99).
To elucidate whether LRT would benefit any particular group of
patients with HCC within the MC, outcomes were analysed for
three subgroups of patients according to whether they demon-
strated a single lesion measuring <3 cm (n = 129), a single lesion
measuring 3–5 cm (n = 28) or multiple lesions (n = 68). There was
no difference (P = 0.61) in 1-year (95.4% vs. 96.1%), 3-year
(90.2% vs. 85.0%) or 5-year (77.3% vs. 80.0%) overall survival
between patients receiving or not receiving LRT in the group with
single lesions measuring <3 cm. Similarly, there was no difference
(P = 0.48) in 1-year (92.3% vs. 92.3%), 3-year (84.6% vs. 92.3%)
or 5-year (67.3% vs. 92.3%) overall survival between patients
receiving or not receiving LRT in the group with single HCC
lesions measuring 3–5 cm. There was no difference (P = 0.51) in
1-year (90.3% vs. 82.9%), 3-year (78.1% vs. 69.6%) or 5-year
(55.9% vs. 62.6%) overall survival between patients receiving or
not receiving LRT in the group with multifocal lesions. Compari-
sons of disease-free survival in patients treated and not treated
with LRT showed no difference (P = 0.41) among patients with
single HCC lesions measuring <3 cm in 1-year (95.4% vs. 94.7%),
3-year (77.7% vs. 79%) or 5-year (62.8% vs. 76%) survival, no
differences (P = 0.28) among patients with single lesions measur-
ing 3–5 cm in 1-year (84.6% vs. 92.3%), 3-year (76.2% vs. 92.3%)
or 5-year (53.8% vs. 82.3) survival (Fig. 3), and no differences
(P = 0.77) among patients with multifocal lesions in 1-year
(80.0% vs. 80.1%), 3-year (69.9% vs. 68.5%) or 5-year (63.0% vs.
60.0%) survival (Fig. 4).
Discussion
Although pre-transplant LRT is widely accepted as able to down-
stage HCC to meet MC requirements, or to treat MC-compliant
HCC if the expected waitlist time is >6 months, its apparent lack
of benefit does not indicate its application in MC HCC patients
with short waitlist times. Although no large RCTs have compared
outcomes in pre-transplantation treated vs. non-treated MC HCC
patients, small single-centre studies indicate that there is no dif-
ference in post-transplant patient survival or tumour recurrence
rate in the setting of short waitlist time.14
Although it would appear that treating small tumours with a
high chance of inducing total tumour necrosis followed by rapid
transplantation (within 3 months of LRT) may set a basis for cure,
8–12% of patients with MC HCC will develop post-transplant
tumour recurrence independently of pre-transplant manage-
ment.17 In the absence of accurate biomarkers indicating residual
disease, this is considered likely to relate to the lack of acknowl-
edgement of micro-metastasis at the time of treatment.
In this retrospective study, data for 225 HCC patients with
MC-compliant disease (out of 275 HCC patients) who underwent
LT were analysed. Patient outcomes and histopathologic tumour
characteristics were compared in 93 patients who received neoad-
juvant LRT and 132 patients who did not. The median waitlist
time prior to transplantation in this population was short, at 48.0
days, and close to the median waitlist time reported across United
Network for Organ Sharing (UNOS) regions during the post-
MELD era until 2006.18 It is also of note that among all UNOS
regions, Region 10, in which the centres in which the present study
was conducted are located, reported the shortest median waiting
time (2.7 weeks) for HCC patients who fulfilled MC requirements
during the post-MELD era until 2009.19 The median waiting
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Figure 2 Kaplan–Meir survival curves: disease-free survival in the
treated and non-treated groups (P = 0.94). LRT, loco-regional
therapy
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period recommended by the American Association for the Study
of Liver Diseases (AASLD) guidelines1 for the application of
neoadjuvant LRT in patients with MC HCC.
In the present study population, MELD scores at listing were
lower in the LRT group, but the difference was less noticeable at
transplantation. The better tolerance of LRT of patients with more
preserved liver function explains this disparity, which has also
been reported in other studies.14 Most of the 93 patients to whom
LRT was delivered received a once-only treatment and only seven
(7.5%) patients received more than one session of therapy (mean:
1.2 sessions). The most frequently used modalities were TACE
(62.4%), RFA (30.1%) and DEB (9.7%).
In the present study, the HCC recurrence rate over a mean
follow-up of 32.2 months was 10.7%, and 1-, 3- and 5-year
disease-free survival rates were 91.1%, 79.3% and 70.6%, respec-
tively (Fig. 2). These findings are similar to historical data.3,20,21 No
differences in patient survival or tumour recurrence rate emerged
between the groups who did and did not receive LRT. This finding
Table 3 Analysis of patients by pathological response following loco-regional therapy (LRT)
Complete response
(n = 16, 17.2%)
Others
(n = 77, 82.8%)
P-value
Diagnosis of hepatitis C, n (%) 11 (68.8) 48 (62.3) 0.65
Number of lesions, mean  SD 1  0.8 1.7  0.9 0.01
Largest lesion size, cm, mean  SD 2.7  1.5 2.8  1.3 0.80
Total tumour diameter, cm, mean  SD 3.6  1.1 3.9  2.1 0.77
Waiting time from LRT, days, mean  SD 38  42.4 61.4  27 0.43
Waiting time from LRT, days, median (25–75% CI) 38 (8–68) 59 (42–83) 0.43
Number of neoadjuvant therapies, mean  SD 1.2  0.4 1.1  0.7 0.34
Waiting time, days, mean  SD 118  130 79.8  119 0.06
Waiting time, days, median (25–75% CI) 72.5 (47–133.5) 50 (27.3–86) 0.06
Differentiation: well, n (%) 2 (12.5) 9 (11.7) <0.001
Overall survival, months, mean  SD 41.4  43 27.6  31 0.27
Disease-free survival, months, mean  SD 38.1  38 26.2  31.5 0.24
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Figure 3 Kaplan–Meir survival curves: disease-free survival in
patients with single hepatocellular carcinoma lesions measuring
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Figure 4 Kaplan–Meir survival curves: disease-free survival in multi-
focal hepatocellular carcinoma lesions in the treated and non-
treated groups (P = 0.77). LRT, loco-regional therapy
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concords with results reported by the only other similar study to
be published,14 which compared outcomes in 31 patients who
received pre-transplant LRT with those in 33 patients undergoing
transplantation without previous LRT. Among the 31 patients
who received LRT, 23 were listed in the MELD era and their mean
 SD waiting time was 54  61 days. This study found similar
survival rates in the treated and untreated groups of 87.5% for
overall survival and 71–75% for disease-free survival, over a
follow-up of 36 months.
In the present study, tumours that had been staged as within the
MC by imaging using triphasic CT or MRI were found to be
understaged according to the analysis of explanted specimens in
23.1% of patients (Table 2). Similar rates (20.5–43.0%) of under-
staging by radiology have been documented by others.11–13 Analy-
sis showed significant increases in the mean number of lesions
(1.8 vs. 1.3; P = 0.03) and size of lesions (3.2 cm vs. 2.1 cm;
P  0.001) in this group of patients compared with those who
were correctly staged.
Given that the MC cover a diverse range of HCC tumours, a
subgroup analysis was performed in an effort to elucidate
whether outcomes would differ among groups according to the
number or size of tumours (single lesions of <3 cm, single
lesions of 3–5 cm, multifocal disease). No disparity in patient
survival or tumour recurrence was noticed in the groups with,
respectively, single lesions of <3 cm (overall survival, P = 0.61;
disease-free survival, P = 0.41), single lesions of 3–5 cm (overall
survival, P = 0.48; disease-free survival, P = 0.28) (Fig. 3),
or multifocal disease (overall survival, P = 0.51; disease-free
survival, P = 0.77) (Fig. 4).
The occurrence of tumour necrosis of 60% has been associ-
ated with increased disease-free survival.22,23 In the present study,
pathology analyses indicated that 16 (17.2%) patients achieved
complete tumour necrosis induced by pre-transplant LRT and
exhibited a 5-year recurrence-free survival rate of 100%. Given
that the ideal goal of LRT is to achieve total tumour necrosis, it
appears that current technologies are still evolving and that a
minimal number of patients are treated completely.
Accordingly, and in view of the lack of accurate biomarkers that
facilitate the recognition of patients who will develop post-
transplant tumour recurrence, time has come to represent a diag-
nostic tool to unveil tumour behaviour. Yao et al.4 showed that
when HCC patients in whom disease characteristics initially
exceeded MC requirements were downstaged and remained
within the MC without evidence of tumour progression over a
period of time (3 months), they achieved post-transplant out-
comes similar to those of patients whose disease initially fell
within MC requirements.4 In an effort to reduce current recur-
rence rates in MC HCC patients, Roberts et al.15 proposed the
application of an ‘ablating and waiting’ protocol in this patient
population and raised concerns about rapid transplantation
(within 3 months following LRT) as applied in some centres with
short waitlist times. An RCT comparing post-transplant outcomes
in patients who do not show disease progression after LRT during
an observation period of 3–6 months with outcomes in patients
who do develop disease progression would be worth considering.
The rationale behind this initiative is solid and relates to the
current scarcity of organs and the need to optimize organ utiliza-
tion and patient selection.
The present study has some drawbacks. It is retrospective in
nature and was performed at two different transplant centres
using a population treated over a period of 7 years. The treating
physicians involved have been multiple, and LRT modalities,
imaging technologies and ways of interpreting tumour response
to therapy have changed or varied. The majority of the study
patients (57.3%) across both groups had small tumours, a char-
acteristic that can be considered as a surrogate for favourable
biologic behaviour, and hence the significance of LRT may have
been minimized. This possibility is again supported by the fact
that a relatively higher number of untreated than treated patients
had well differentiated tumours. However, the study’s significance
is supported by the large number of patients involved, which
makes it one of the largest retrospective studies of its nature.
In conclusion, based on this and other studies, LRT followed by
rapid transplantation in MC HCC patients does not appear to
impact on post-transplant outcome and its indication is without
solid foundation. Indications for LRT in selected patients with
single lesions of 3–5 cm or multifocal disease also remain ques-
tionable, but further studies are required to investigate outcomes
in these subgroups. Further strategies to identify the 10% of
patients who will develop tumour recurrence must be sought. The
role of LRT in the setting discussed in this study may change in
light of future evolutions in technology and the search for accu-




1. Bruix J, Sherman M. (2011) American Association for the Study of
Liver Diseases. Management of hepatocellular carcinoma: an update.
Hepatology 53:1020–1022.
2. Huang J, Yan L, Cheng Z, Wu H, Du L, Wang J et al. (2010) A randomized
trial comparing radiofrequency ablation and surgical resection for HCC
conforming to the Milan Criteria. Ann Surg 252:903–912.
3. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F et al.
(1996) Liver transplantation for the treatment of small hepatocellular
carcinomas in patients with cirrhosis. N Engl J Med 334:693–699.
4. Yao FY, Hirose R, LaBerge JM, Davern TJ, 3rd, Bass NM, Kerlan RK et al.
(2005) A prospective study on downstaging of hepatocellular carcinoma
prior to liver transplantation. Liver Transpl 11:1505–1514.
5. Yao FY, Kerlan RK Jr, Hirose R, Davern TJ, 3rd, Bass NM, Feng S et al.
(2008) Excellent outcome following downstaging of hepatocellular
carcinoma prior to liver transplantation: an intention-to-treat analysis.
Hepatology 48:819–827.
6. Barakat O, Wood RP, Ozaki CF, Ankoma-Sey V, Galati J, Skolkin M et al.
(2010) Morphological features of advanced hepatocellular carcinoma as a
predictor of downstaging and liver transplantation: an intention-to-treat
analysis. Liver Transpl 16:289–299.
HPB 331
HPB 2012, 14, 325–332 © 2012 International Hepato-Pancreato-Biliary Association
7. Duffy JP, Vardanian A, Benjamin E, Watson M, Farmer DG, Ghobrial RM
et al. (2007) Liver transplantation criteria for hepatocellular carcinoma
should be expanded: a 22-year experience with 467 patients at UCLA.
Ann Surg 246:502–509; discussion 509–511.
8. Lewandowski RJ, Mulcahy MF, Kulik LM, Riaz A, Ryu RK, Baker TB et al.
(2010) Chemoembolization for hepatocellular carcinoma: comprehensive
imaging and survival analysis in a 172-patient cohort. Radiology 255:955–
965.
9. Vitale A, Boccagni P, Brolese A, Neri D, Srsen N, Zanus G et al.
(2009) Progression of hepatocellular carcinoma before liver trans-
plantation: dropout or liver transplantation? Transplant Proc 41:1264–
1267.
10. Freeman RB, Wiesner RH, Edwards E, Harper A, Merion R, Wolfe R et al.
(2004) Results of the first year of the new liver allocation plan. Liver
Transpl 10:7–15.
11. Chao SD, Roberts JP, Farr M, Yao FY. (2007) Short waitlist time does not
adversely impact outcome following liver transplantation for hepatocel-
lular carcinoma. Am J Transplant 7:1594–1600.
12. Mejia GA, Gomez MA, Serrano J, Garcia I, Tamayo MJ, Pareja F et al.
(2006) Correlation between the radiologic and histologic size of hepato-
cellular carcinoma in patients eligible for liver transplantation. Transplant
Proc 38:1394–1395.
13. Shah SA, Tan JC, McGilvray ID, Cattral MS, Cleary SP, Levy GA et al.
(2006) Accuracy of staging as a predictor for recurrence after liver
transplantation for hepatocellular carcinoma. Transplantation 81:1633–
1639.
14. Porrett PM, Peterman H, Rosen M, Sonnad S, Soulen M, Markmann JF
et al. (2006) Lack of benefit of pre-transplant locoregional hepatic therapy
for hepatocellular cancer in the current MELD era. Liver Transpl 12:665–
673.
15. Roberts JP, Venook A, Kerlan R, Yao F. (2010) Hepatocellular carcinoma:
ablate and wait versus rapid transplantation. Liver Transpl 16:925–929.
16. Sherman M. (2010) The radiological diagnosis of hepatocellular carci-
noma. Am J Gastroenterol 105:610–612.
17. Parfitt JR, Marotta P, Alghamdi M, Wall W, Khakhar A, Suskin NG et al.
(2007) Recurrent hepatocellular carcinoma after transplantation: use of a
pathological score on explanted livers to predict recurrence. Liver Transpl
13:543–551.
18. Pelletier SJ, Fu S, Thyagarajan V, Romero-Marrero C, Batheja MJ,
Punch JD et al. (2009) An intention-to-treat analysis of liver transplanta-
tion for hepatocellular carcinoma using organ procurement transplant
network data. Liver Transpl 15:859–868.
19. Kadry Z, Schaefer EW, Uemura T, Shah AR, Schreibman I, Riley TR.
(2012) Impact of geographic disparity on liver allocation for hepatocellular
cancer in the United States. J Hepatol 56:618–625.
20. Decaens T, Roudot-Thoraval F, Hadni-Bresson S, Meyer C, Gugenheim
J, Durand F et al. (2006) Impact of UCSF criteria according to pre- and
post-OLT tumour features: analysis of 479 patients listed for HCC with a
short waiting time. Liver Transpl 12:1761–1769.
21. Lee FT Jr. (2007) Treatment of hepatocellular carcinoma in cirrhosis:
locoregional therapies for bridging to liver transplant. Liver Transpl 13
(Suppl. 2):24–26.
22. Chan KM, Yu MC, Chou HS, Wu TJ, Lee CF, Lee WC. (2011) Significance
of tumour necrosis for outcome of patients with hepatocellular carcinoma
receiving locoregional therapy prior to liver transplantation. Ann Surg
Oncol 18:2638–2646.
23. Millonig G, Graziadei IW, Freund MC, Jaschke W, Stadlmann S, Ladurner
R et al. (2007) Response to preoperative chemoembolization correlates
with outcome after liver transplantation in patients with hepatocellular
carcinoma. Liver Transpl 13:272–279.
332 HPB
HPB 2012, 14, 325–332 © 2012 International Hepato-Pancreato-Biliary Association
